Please use this identifier to cite or link to this item:
|Title:||Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 ` final results of the REV1TAL study|
Dore, Gregory J.
et al, Various
Gow, Paul J
Iser, David M.
Jones, Tracey L.
Mitchell, Joanne L.
Stuart, Katherine Anne
Thompson, Alexander James V.
Westmead Clinical School: Westmead Institute for Medical Res
|Publisher:||International Medical Press|
|Citation:||Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 ` final results of the REV1TAL study, Antiviral Therapy, vol.22, 8, 2017,pp 699-710|
|Department/Unit/Centre:||Westmead Clinical School: Westmead Institute for Medical Res|
|Disclaimer:||This work has been made available to the staff and students of the University of Sydney for the purposes of research and study only. It constitutes material that is held by the University for the purposes of reporting for HERDC and the ERA. This work may not be downloaded, copied and distributed to any third party .|
|Type:||C1 - Refereed Journal articles|
|Appears in Collections:||University of Sydney Research Outputs|
Items in Sydney Research Online are protected by copyright, with all rights reserved, unless otherwise indicated.